Mensinger Mike 4

What Happened
Mike Mensinger, Chief Product Officer of Beta Bionics (BBNX), sold 4,378 shares on June 2, 2026. The reported proceeds from the sale were $55,194. The transaction was a sale (reported as "S") and was made to cover tax withholding obligations tied to the vesting of restricted stock units.

Key Details

• Transaction date: 2026-06-02; Form 4 filed 2026-06-03.
• Type: Sale (open-market or private sale reported as "S").
• Shares sold: 4,378; reported total proceeds: $55,194.
• Prices: weighted average $12.6071; reported price range $12.30–$12.93. (Per the filing, full breakdown of shares sold at each price is available on request.)
• Reason: Footnote states sale was to cover tax withholding for vested RSUs.
• Shares owned after the transaction: not provided in the excerpt of the filing.
• Timeliness: filing date is the day after the transaction; no late-filing indication provided.

Context
Sales to cover tax withholding for vested restricted stock units are common and typically routine administrative transactions rather than direct signals of confidence or concern about the company’s outlook. For investors, purchases by insiders are generally more informative about sentiment than tax-related sales.